In November 2025, Merz Aesthetics announced that Ultherapy PRIME had received FDA 510(k) clearance to improve the appearance of skin laxity on the anterior arms, posterior arms, and abdomen. With the new clearance, Ultherapy PRIME became the only FDA-cleared microfocused ultrasound device with real-time visualization cleared to treat the face, neck, décolleté, and body.
That last sentence has a lot of qualifiers, and each one matters. This article breaks down what Ultherapy PRIME actually is, how it differs from the original Ultherapy platform that has been in clinical use since 2009, what the expanded body clearance means, what the evidence shows, and what patients should ask before booking.
What Ultherapy PRIME is
Ultherapy PRIME is a microfocused ultrasound with visualization (MFU-V) device manufactured by Merz Aesthetics (through its subsidiary Ulthera, Inc.). It delivers focused ultrasound energy to specific depths in the skin's dermal and subdermal layers, creating thermal coagulation points that stimulate the body's natural wound-healing response — specifically, neocollagenesis (new collagen formation) and elastogenesis (new elastin formation).
The key differentiator is real-time visualization. The DeepSEE transducer allows the provider to see tissue layers up to 8 mm below the skin surface on a screen during treatment. This serves two purposes: it confirms that the ultrasound energy is being delivered to the correct depth (superficial dermis at 1.5 mm, deep dermis at 3.0 mm, or SMAS/platysma at 4.5 mm), and it helps the provider avoid bone, blood vessels, and other non-target structures.
What changed from legacy Ultherapy
The original Ultherapy system has been in clinical use since its first FDA clearance in 2009. Over 3.5 million treatments have been performed globally, and the system has been described as the "gold standard" in non-invasive skin lifting, with a 95% patient satisfaction rate at one year in manufacturer-reported data.
Ultherapy PRIME is not a new mechanism. It is the same microfocused ultrasound technology with visualization, updated in three practical ways:
1. Improved visualization
- 35% larger screen with reduced visual noise for clearer imaging
- 72% clearer imaging compared to legacy Ultherapy, according to Merz Aesthetics
- 2× larger ultrasound field for wider treatment coverage per placement
- Improved depth visualization up to 8 mm, allowing providers to more precisely target the SMAS layer and deep dermis
2. Faster treatment
- 20% faster treatments on average compared to legacy Ultherapy, based on provider surveys
- Updated processor, operating system, and drivers for smoother operation
- The See-Plan-Treat protocol — a structured framework for using real-time visualization during treatment planning and delivery
3. Improved patient comfort
- Average pain scores less than half those reported with legacy Ultherapy, according to Merz Aesthetics clinical data
- The original Ultherapy was frequently cited as one of the more painful non-invasive aesthetic treatments. Patient discomfort was significant enough that many practices offered oral analgesics or numbing cream as standard protocol. The improvement in comfort with PRIME is one of the more clinically relevant upgrades.
What did not change
- The mechanism of action is the same: microfocused ultrasound creating thermal coagulation points at targeted depths
- The treatment depths are the same: 1.5 mm, 3.0 mm, and 4.5 mm with multi-depth transducers
- The results timeline is the same: some immediate tightening from collagen contraction, with full results developing over 2–3 months as neocollagenesis progresses
- It remains a single-session treatment with no downtime (patients may experience redness, swelling, or tenderness for a few hours to days)
The November 2025 body clearance
The FDA 510(k) clearance (K243035, submitted by Ulthera, Inc.) expanded Ultherapy PRIME's indications to include:
- Anterior arms (front of the upper arm)
- Posterior arms (back of the upper arm — the "bat wing" area)
- Abdomen (peri-umbilical and lower abdomen)
Prior to this clearance, Ultherapy PRIME was FDA-cleared for:
- Lifting the eyebrow
- Lifting skin on the neck and under the chin
- Improving lines and wrinkles on the décolleté
The body clearance was supported by a comprehensive literature review of seven clinical studies that used the Ulthera System to treat skin laxity on the abdomen, anterior arms, and posterior arms, as documented in the 510(k) summary filed with the FDA.
What this means practically
The body clearance addresses a gap in non-invasive treatment options. Before Ultherapy PRIME's body clearance, patients with skin laxity on the arms or abdomen had limited non-surgical choices:
- Radiofrequency devices (Thermage, Sofwave) can treat some body areas but operate at more superficial depths and do not have real-time visualization to the same degree
- Surgical brachioplasty (arm lift) and abdominoplasty (tummy tuck) remain the gold standard for significant laxity, but carry the risks and recovery of surgery
- Injectable biostimulators (hyperdilute Radiesse, Sculptra) are increasingly used off-label for skin tightening on the body, but do not have FDA clearance for body skin laxity specifically
Ultherapy PRIME's body clearance does not replace surgery for significant laxity. It is positioned for mild to moderate skin laxity — patients who are not surgical candidates, or who want to delay surgery.
Important anatomy considerations for body treatment
Dr. Jennifer Levine, a double board-certified facial plastic surgeon in New York City who has been using Ultherapy PRIME, noted in The Dermatology Digest that there are specific anatomical considerations for body treatments:
- No-treatment zones directly over the umbilicus
- Avoid the ulnar nerve on the posterior arm — this is a superficial nerve that could be at risk if ultrasound energy is delivered at the wrong depth or location
- Knowing the anatomy of the treatment area is critical — the body clearance should not be treated as a simple extension of facial technique
The GLP-1 connection
The body clearance is timely. With the rapid expansion of GLP-1 receptor agonist use (semaglutide/Ozempic/Wegovy, tirzepatide/Mounjaro/Zepbound), a growing patient population has achieved significant weight loss and now faces skin laxity on the arms and abdomen as a secondary concern. As Dr. Levine noted: "These people are thin but can't wear a bikini or sleeveless dress because laxity, sagginess, or crepiness impacts their clothing choices. Patients aren't as concerned with fat anymore. Instead, they are mainly concerned with their skin quality."
What the evidence shows
The clinical evidence base for microfocused ultrasound with visualization (MFU-V) is growing but still limited compared to surgical alternatives.
A pilot case series published in PMC in 2025 examining early experience with Ultherapy PRIME in the Asia-Pacific region found that the updated system's improved visualization enabled more precise treatment planning and delivery. The study confirmed that MFU-V creates consistent thermal coagulation points at targeted depths, stimulating neocollagenesis and elastogenesis with subsequent tissue remodeling and tightening.
Key evidence points:
- Over 3.5 million Ultherapy treatments have been performed globally (both legacy and PRIME), providing a large real-world safety database
- A 2016 study by Werschler and Werschler in the Journal of Clinical Aesthet Dermatology demonstrated long-term efficacy of MFU-V for lifting and tightening facial and neck skin using a customized vectoring treatment method
- Manufacturer-reported data shows 95% patient satisfaction at one year for facial treatments
- The body clearance was supported by seven clinical studies in the 510(k) submission, though longer-term body-specific outcome data is still being collected
- Results on the face can last up to a year or more; results on the body are described as lasting six months or more according to Merz Aesthetics
The limitation: most of the published clinical data for Ultherapy focuses on facial and neck applications. Body-specific outcomes (arms, abdomen) have a smaller evidence base, and the duration claim for body results (6+ months) is shorter than for facial results (12+ months), which patients should understand.
What Ultherapy PRIME cannot do
- It is not a substitute for surgery in patients with significant skin laxity, excess skin, or diastasis recti. A patient who needs a tummy tuck will not get an equivalent result from Ultherapy PRIME.
- It does not remove fat. Ultherapy PRIME targets skin and connective tissue. Patients with both fat and skin laxity may need a combined approach (e.g., liposuction plus Ultherapy PRIME, or CoolSculpting followed by skin tightening).
- Results are not immediate. Some tightening from collagen contraction is visible early, but full results take 2–3 months as new collagen forms. Patients should not judge the outcome at one week.
- It does not work equally well for everyone. Results depend on the degree of laxity, the quality of the patient's collagen, age, and the depth and energy settings used by the provider.
- Body results may not last as long as facial results. The skin on the arms and abdomen is subject to more movement and stretching than facial skin, which may affect longevity.
Cost considerations
Ultherapy PRIME is a premium treatment. As of 2026, cost ranges in the United States are approximately:
- Face and neck: $2,500–$5,000 per session
- Décolleté: $1,500–$3,000 per session
- Arms (anterior and/or posterior): $2,000–$4,000 per session
- Abdomen: $2,500–$5,000 per session
Costs vary by market, provider experience, and the number of areas treated in a single session. Because results are gradual and may not be as dramatic as surgery, patients should weigh the cost against the expected degree of improvement for their specific degree of laxity.
Legacy Ultherapy support ending
Merz Aesthetics has announced that support for the legacy Ultherapy platform will conclude on September 30, 2027. Practices still using the original system will be provided transition resources during the wind-down period. Patients who are mid-treatment course on the legacy platform should discuss the transition timeline with their provider.
What patients should ask
- "Are you using Ultherapy PRIME or the legacy system?" The two platforms are different. PRIME offers better imaging, faster treatment, and improved comfort. If a practice is still on the legacy system, the experience may be different from what current marketing describes.
- "How many body treatments have you performed?" The body clearance is recent. A provider who has extensive facial Ultherapy experience but limited body experience is not the same as one who has been treating arms and abdomens since the clearance.
- "What results can I realistically expect for my degree of laxity?" Ultherapy PRIME works best for mild to moderate laxity. If a provider promises surgical-level results from a non-invasive treatment, that is a red flag.
- "Can you show me the real-time visualization during treatment?" One of the advantages of Ultherapy PRIME is that the provider can — and should — use the imaging to confirm proper depth and avoid non-target structures. If a provider is not using the visualization, they are not using the device to its full capability.
- "Is my skin laxity appropriate for Ultherapy PRIME, or would I be better served by surgery?" A good provider will tell you when a non-invasive treatment is unlikely to achieve the result you want. If you have significant excess skin after major weight loss, you may need a surgical referral, not a device treatment.
Sources
- Merz Aesthetics / American Med Spa Association — Ultherapy PRIME Gains FDA Clearance for Abdomen, Arms: https://www.americanmedspa.org/news/ultherapy-prime-gains-fda-clearance-to-treat-abdomen-arms-becomes-only-solution-with-real-time-imaging-for-face-neck-decollete-and-body
- FDA 510(k) Summary K243035 — Ulthera System Expanded Indications: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243035.pdf
- Ultherapy — Official Product Page (Ultherapy PRIME): https://ultherapy.com
- The Dermatology Digest — FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomen: https://thedermdigest.com/u-s-fda-clears-ultherapy-prime-to-treat-skin-laxity-on-the-arms-and-abs
- NewBeauty — Ultherapy PRIME Earns FDA Clearance for Skin-Tightening on Arms and Abdomen: https://www.newbeauty.com/view/ultherapy-prime-fda-approved-for-skin-tightening-on-arms-and-abdomen
- PMC — Early Experience With Ultherapy Prime in Asia Pacific: A Pilot Case Series: https://pmc.ncbi.nlm.nih.gov/articles/PMC12637326
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin. J Clin Aesthet Dermatol. 2016;9(2):27-33.
